A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol
Top Cited Papers
- 1 November 2018
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 122 (5), 783-793
- https://doi.org/10.1111/bju.14374
Abstract
BackgroundObjectives and MethodsAccurate staging of patients with prostate cancer (PCa) is important for therapeutic decision-making. Relapse after surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is a new whole-body scanning technique that enables visualization of PCa with high contrast. The hypotheses of this study are that: (i) PSMA-PET/CT has improved diagnostic performance compared with conventional imaging; (ii) PSMA-PET/CT should be used as a first-line diagnostic test for staging; (iii) the improved diagnostic performance of PSMA-PET/CT will result in significant management impact; and (iv) there are economic benefits if PSMA-PET/CT is incorporated into the management algorithm. The proPSMA trial is a prospective, multicentre study in which patients with untreated high-risk PCa will be randomized to gallium-68-PSMA-11 PET/CT or conventional imaging, consisting of CT of the abdomen/pelvis and bone scintigraphy with single-photon emission CT/CT. Patients eligible for inclusion are those with newly diagnosed PCa with select high-risk features, defined as International Society of Urological Pathology grade group 3 (primary Gleason grade 4, or any Gleason grade 5), prostate-specific antigen level 20ng/mL or clinical stage T3. Patients with negative, equivocal or oligometastatic disease on first line-imaging will cross over to receive the other imaging arm. The primary objective is to compare the accuracy of PSMA-PET/CT with that of conventional imaging for detecting nodal or distant metastatic disease. Histopathological, imaging and clinical follow-up at 6months will define the primary endpoint according to a predefined scoring system. Secondary objectives include comparing management impact, the number of equivocal studies, the incremental value of second-line imaging in patients who cross over, the cost of each imaging strategy, radiation exposure, inter-observer agreement and safety of PSMA-PET/CT. Longer-term follow-up will also assess the prognostic value of a negative PSMA-PET/CT. Outcome and SignificanceThis trial will provide data to establish whether PSMA-PET/CT should replace conventional imaging in the primary staging of select high-risk localized PCa, or whether it should be used to provide incremental diagnostic information in selected cases.Funding Information
- Prostate Cancer Foundation of Australia (PCFA – CTA 1815)
This publication has 39 references indexed in Scilit:
- The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2013
- Prognostic Gleason grade grouping: data based on the modified Gleason scoring systemBJU International, 2013
- Is there still a role for SPECT–CT in oncology in the PET–CT era?Nature Reviews Clinical Oncology, 2012
- A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancerEJNMMI Research, 2012
- 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET ImagingBioconjugate Chemistry, 2012
- Diagnostic Performance of In-111 Capromab Pendetide SPECT/CT in Localized and Metastatic Prostate CancerClinical Nuclear Medicine, 2011
- Converting Dose-Length Product to Effective Dose at CTRadiology, 2008
- Practice-Based Evidence Study Design for Comparative Effectiveness ResearchMedical Care, 2007
- [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- A comparison of methods for calculating a stratified kappaStatistics in Medicine, 1991